Middle East and Africa Drug-Device Combination Market – Industry Trends and Forecast to 2028

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Middle East and Africa Drug-Device Combination Market – Industry Trends and Forecast to 2028

  • Healthcare
  • Published Report
  • Sep 2021
  • MEA
  • 350 Pages
  • No of Tables: 40
  • No of Figures: 46

Middle East and Africa Drug-Device Combination Market, By Product (Auto-Injector, Microneedle Patch, Digital Pill, Smart Inhaler, Drug Delivery Hydrogels, Drug-Eluting Lens and Others), Application Type (Orthopedic Diseases, Respiratory Diseases, Diabetes, Oncology, Cardiovascular Diseases, and Others), End User (Clinics, Hospitals, Home Care Settings, Ambulatory Care Centers and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (South Africa and Rest of Middle East and Africa) Industry Trends and Forecast To 2028.

Middle East and Africa Drug-Device Combination Market

Market Analysis and Insights: Middle East and Africa Drug-Device Combination Market

Drug-Device combination market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.7% in the forecast period of 2021 to 2028 and is expected to reach USD 1,274.40 million by 2028 from USD 678.90 million in 2020. Increasing demand for medical devices, rising government initiatives are the major drivers which boost the demand of the market in the forecast period.

Increasing prevalence of chronic diseases advancement in technology effectively helps the growth of the drug-device combination market. However, the limitations and complications associated with the drug-device combination products may hamper the future growth of the drug-device combination market. The partnerships and collaborations by major market players act as an opportunity. However, strict regulatory framework act as a challenge for the growth of the drug-device combination market.

The drug-device combination market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Drug-Device Combination Market

Middle East and Africa Drug-Device Combination - Market Scope and Market Size

Middle East and Africa drug-device combination market is categorized into four notable segments, which are based on product, application, end user, and distribution channel. 

  • On the basis of product, the drug-device combination market is segmented into auto-injector, microneedle patch, digital pill, smart inhaler, drug delivery hydrogels, drug-eluting lens, and others. In 2021, auto-injector holds the highest share in the medical devices market as growing demand for highly advanced and efficient drug-device combination technology for treatment.
  • On the basis of application, the drug-device combination market is segmented into orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, and others. In 2021, the orthopedic is expected to dominate the drug-device combination market due to increased potential for technological growth, especially in medical devices and healthcare segments, coupled with the increasing availability of advanced medical aids for prevalent health conditions anticipated to propel further market growth.
  • On the basis of end user, the drug-device combination market is segmented into clinics, hospitals, home care settings, ambulatory care centers, and others. In 2021, the clinics are expected to dominate the drug-device combination market because most patients prefer to monitor and take treatment from experts in order to avoid further complications.
  • On the basis of distribution channel, the drug-device combination market is segmented into direct tender, retail sales, and others. In 2021, the direct tender is expected to dominate the drug-device combination market due to more availability of hospitals and clinics combined with growing international trade systems.

Drug-Device Combination Market Country Level Analysis

The drug-device combination market is analyzed, and market size information is provided by product, application, end user, and distribution channel.

The countries covered in the drug-devices combination market report are South Africa and Rest of Middle East and Africa.

South Africa is expected to grow with a substantial growth rate in the forecast period of 2021 to 2028 in Middle East and African countries. The government bodies and healthcare organizations are undertaking various programs in this region; consequently, it is anticipated to propel market growth.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of the Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Growing Partnership and Distribution Agreement with Local Players is Creating New Opportunities for Players in the Drug-Device Combination Market 

The drug-device combination market also provides you with a detailed market analysis for every country's growth in the drug-device combination product industry. Additionally, it provides detailed information regarding growing partnership and distribution agreements with local players. The data is available for the historical period 2010 to 2019. 

Competitive Landscape and Market Share Analysis

Drug-Device combination market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the drug-device combination market.

The major players covered in the report are Medtronic, Amgen Inc., B.D., Eitan Medical, E3D Elcam Drug Delivery Devices, GlaxoSmithKline plc, Bayer AG, NanoPass, Janssen Pharmaceuticals, Inc.(a subsidiary of Johnson & Johnson Sevices, Inc.), Otsuka America Pharmaceutical, Inc., among other domestic and Middle East and Africa players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product approvals are also initiated by companies worldwide, which are also accelerating the drug-device combination market.

For instance,  

  • In July 2021, Eitan Medical announced the expansion of its business by the opening of the German Head Office. This expansion to Europe increased the support of a growing customer base
  • In October 2020, Glaxosmithkline Plc announced that the European Medicines Agency (EMA) had accepted regulatory submissions seeking approval for the use of anti-IL5 biologic Nucala (mepolizumab) in three additional conditions: hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). This has increased the company’s revenue, thereby attracted more customers towards their company
  • In September 2018, Amgen Inc. received marketing approval from the Japanese Ministry of Health, Labour, and Welfare for Blincyto (blinatumomab). The first line usage of Blincyto (blinatumomab) is to treat relapsed or refractory B-cell acute lymphoblastic leukemia. This approval has accelerated the company's position in the Japanese market

Collaboration, joint ventures, and other strategies by the market player are enhancing the company presence in the drug-device combination market, which also provides benefit for the organization.   

 

 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PATENT ANALYSIS

4.1.1 MANUFACTURING PROCESS OF COMBINATION PRODUCTS

4.1.2 APPROVAL BY AGENCY

4.1.3 PATENT GRANT

4.1.4 PATENT CERTIFICATIONS:

5 PIPELINE ANALYSIS

6 REGULATORY FRAMEWORKS:

6.1 U.S.

6.2 EUROPE

6.3 CANADA

6.4 AUSTRALIA

6.5 JAPAN

6.6 CHINA

6.7 SOUTH KOREA

7 REGIONAL SUMMARY

7.1 NORTH AMERICA DRUG-DEVICE COMBINATION MARKET

7.1.1 OVERVIEW

7.2 EUROPE DRUG-DEVICE COMBINATION MARKET

7.2.1 OVERVIEW

7.3 ASIA-PACIFIC DRUG-DEVICE COMBINATION MARKET

7.3.1 OVERVIEW

7.4 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET

7.4.1 OVERVIEW

7.5 SOUTH AMERICA DRUG-DEVICE COMBINATION MARKET

7.5.1 OVERVIEW

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

8.1.2 GROWING GERIATRIC POPULATION

8.1.3 ESCALATION IN INNOVATION AND TECHNOLOGIES

8.1.4 RISING RATES OF OBESITY

8.2 RESTRAINTS

8.2.1 PRODUCT RECALLS

8.2.2 RISK ASSOCIATED WITH THE COMBINATION PRODUCTS

8.3 OPPORTUNITIES

8.3.1 RISING EXPENDITURE ON HEALTHCARE

8.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

8.3.3 GROWING SUPPORT BY HEALTHCARE ORGANIZATIONS AND GOVERNMENT BODIES

8.3.4 INCREASE IN R&D ACTIVITIES BY MEDICAL DEVICE COMPANIES

8.4 CHALLENGE

8.4.1 STRICT REGULATORY FRAMEWORK

9 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET

9.1 IMPACT ON PRICE

9.2 IMPACT ON SUPPLY CHAIN

9.3 IMPACT ON DEMAND

9.4 STRATEGIC DECISIONS FOR MANUFACTURERS

9.5 CONCLUSION

10 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT

10.1 OVERVIEW

10.2 AUTO-INJECTOR

10.2.1 WEARABLE AUTO-INJECTOR

10.2.2 HAND HELD AUTO-INJECTOR

10.3 MICRONEEDLE PATCH

10.4 DIGITAL PILL

10.5 SMART INHALER

10.6 DRUG DELIVERY HYDROGELS

10.7 DRUG-ELUTING LENS

10.8 OTHERS

11 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION

11.1 OVERVIEW

11.2 ORTHOPEDIC DISEASES

11.3 RESPIRATORY DISEASES

11.4 DIABETES

11.5 ONCOLOGY

11.6 CARDIOVASCULAR DISEASES

11.7 OTHERS

12 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY END USER

12.1 OVERVIEW

12.2 CLINICS

12.3 HOSPITALS

12.4 HOME CARE SETTINGS

12.5 AMBULATORY CARE CENTERS

12.6 OTHERS

13 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 RETAILS SALES

13.4 OTHERS

14 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY REGION

14.1 MIDDLE EAST AND AFRICA

14.1.1 SOUTH AFRICA

14.1.2 REST OF MIDDLE EAST AND AFRICA

15 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 AMGEN INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENTS

17.3 GLAXOSMITHKLINE PLC

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 COMPANY SHARE ANALYSIS

17.3.4 PRODUCT PORTFOLIO

17.3.5 RECENT DEVELOPMENT

17.4 BD

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENTS

17.5 MEDTRONIC

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENTS

17.6 BAYER AG

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 PRODUCT PORTFOLIO

17.6.4 RECENT DEVELOPMENT

17.7 CGBIO

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENTS

17.8 COSMED PHARMACEUTICAL CO.LTD.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENTS

17.9 E3D ELCAM DRUG DELIVERY DEVICES

17.9.1 COMPANY SNAPSHOT

17.9.2 PRODUCT PORTFOLIO

17.9.3 RECENT DEVELOPMENTS

17.1 EITAN MEDICAL

17.10.1 COMPANY SNAPSHOT

17.10.2 PRODUCT PORTFOLIO

17.10.3 RECENT DEVELOPMENTS

17.11 EOFLOW CO., LTD.

17.11.1 COMPANY SNAPSHOT

17.11.2 PRODUCT PORTFOLIO

17.11.3 RECENT DEVELOPMENTS

17.12 FINDAIR SP. Z O. O.

17.12.1 COMPANY SNAPSHOT

17.12.2 PRODUCT PORTFOLIO

17.12.3 RECENT DEVELOPMENT

17.13 INSULET CORPORATION

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENT

17.14 MEDIPRINT

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 METP PHARMA AG

17.15.1 COMPANY SNAPSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 MICRON BIOMEDICAL, INC.

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 NANOPASS

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 OCUMEDIC

17.18.1 COMPANY SNAPSHOT

17.18.2 PRODUCT PORTFOLIO

17.18.3 RECENT DEVELOPMENT

17.19 OTSUKA AMERICA PHARMACEUTICAL, INC.

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENT

17.2 PROPELLER HEALTH

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENT

17.21 RAPHAS CO., LTD.

17.21.1 COMPANY SNAPSHOT

17.21.2 REVENUE ANALYSIS

17.21.3 PRODUCT PORTFOLIO

17.21.4 RECENT DEVELOPMENT

17.22 SENSIRION AG SWITZERLAND

17.22.1 COMPANY SNAPSHOT

17.22.2 REVENUE ANALYSIS

17.22.3 PRODUCT PORTFOLIO

17.22.4 RECENT DEVELOPMENT

17.23 . SONCEBOZ

17.23.1 COMPANY SNAPSHOT

17.23.2 PRODUCT PORTFOLIO

17.23.3 RECENT DEVELOPMENT

17.24 SUBCUJECT APS

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENT

17.25 THERAJECT

17.25.1 COMPANY SNAPSHOT

17.25.2 PRODUCT PORTFOLIO

17.25.3 RECENT DEVELOPMENT

17.26 VAXESS TECHNOLOGIES INC.

17.26.1 COMPANY SNAPSHOT

17.26.2 PRODUCT PORTFOLIO

17.26.3 RECENT DEVELOPMENTS

17.27 VAXXAS

17.27.1 COMPANY SNAPSHOT

17.27.2 PRODUCT PORTFOLIO

17.27.3 RECENT DEVELOPMENTS

17.28 YPSOMED

17.28.1 COMPANY SNAPSHOT

17.28.2 REVENUE ANALYSIS

17.28.3 PRODUCT PORTFOLIO

17.28.4 RECENT DEVELOPMENTS

17.29 ZIMMER BIOMET

17.29.1 COMPANY SNAPSHOT

17.29.2 REVENUE ANALYSIS

17.29.3 PRODUCT PORTFOLIO

17.29.4 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA DRUG-DEVICE COMIBINATION MARKET, PIPELINE ANALYSIS

TABLE 2 MOST OBESE COUNTRIES OF ASIA-PACIFIC 2020

TABLE 3 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA MICRONEEDLE PATCH IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA DIGITAL PILL IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA SMART INHALER IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA DRUG DELIVERY HYDROGELS IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA DRUG-ELUTING LENS IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA ORTHOPEDIC DISEASES IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA DIABETES IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA ONCOLOGY IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA OTHERS IN DRUG-DEVICE COMBINATION MARKET, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA CLINICS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA HOSPITALS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA HOME CARE SETTINGS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA AMBULATORY CARE CENTERS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA AMBULATORY CARE CENTERS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA DIRECT TENDER IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA RETAIL SALES IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN DRUG-DEVICE COMBINATION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 35 SOUTH AFRICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 36 SOUTH AFRICA AUTO-INJECTOR IN DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 37 SOUTH AFRICA DRUG-DEVICE COMBINATION MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 38 SOUTH AFRICA DRUG-DEVICE COMBINATION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 39 SOUTH AFRICA DRUG-DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 40 REST OF MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: PRODUCT TYPE LIFELINE CURVE

FIGURE 8 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: DBMR MARKET POSITION GRID

FIGURE 10 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: VENDOR SHARE ANALYSIS

FIGURE 12 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: SEGMENTATION

FIGURE 13 THE INCREASING PREVALENCE OF CHRONIC DISEASES AND RISING GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 THE AUTO-INJECTOR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET IN THE YEAR 2021 & 2028

FIGURE 15 PORTER'S 5 FORCES

FIGURE 16 PESTEL'S MODEL

FIGURE 17 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES: MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET

FIGURE 18 PREVALENCE OF ASTHMA IN THE FOLLOWING COUNTRIES.

FIGURE 19 INCIDENCE OF CANCER, WHICH INCREASES WITH AGE

FIGURE 20 AGEING POPULATION IN THE WORLD (IN MILLIONS)

FIGURE 21 NORTH AMERICA AGEING POPULATION (IN MILLION)

FIGURE 22 EUROPE AGEING POPULATION (IN MILLION)

FIGURE 23 ASIA-PACIFIC AGEING POPULATION (IN MILLION)

FIGURE 24 MEDICAL DEVICE SPENDING VS. NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 25 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, 2020

FIGURE 26 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, 2019-2028 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 28 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, 2020

FIGURE 30 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 32 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY END USER, 2020

FIGURE 34 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 35 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 36 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 38 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 39 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 40 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: SNAPSHOT (2020)

FIGURE 42 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2020)

FIGURE 43 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 44 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 45 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: BY PRODUCT (2021-2028)

FIGURE 46 MIDDLE EAST AND AFRICA DRUG-DEVICE COMBINATION MARKET: COMPANY SHARE 2020 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Middle East and Africa Drug-Device Combination Market size will be worth USD 1,274.40 million by 2028.
The Middle East and Africa Drug-Device Combination Market growth rate will be 8.7% by 2028.
The Increasing demand for medical devices and rising government initiatives are the growth drivers of the Middle East and Africa Drug-Device Combination Marke.
The product, application, end user, and distribution channel are the factors on which the Middle East and Africa Drug-Device Combination Market research is based.
The major companies in the Middle East and Africa Drug-Device Combination Market are Medtronic, Amgen Inc., B.D., Eitan Medical, E3D Elcam Drug Delivery Devices, GlaxoSmithKline plc, Bayer AG, NanoPass, Janssen Pharmaceuticals, Inc.(a subsidiary of Johnson & Johnson Sevices, Inc.), Otsuka America Pharmaceutical, Inc.